Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
Verve Therapeutics was a clinical-stage company developing genetic medicines for cardiovascular disease before its completed acquisition by Eli Lilly and Company. Its public updates centered on in vivo base-editing programs such as VERVE-102, which targets PCSK9 in the liver to reduce LDL-C, along with clinical and regulatory disclosures, operating and financial results, and equity award activity under Nasdaq inducement-grant rules.
Company news also included investor-conference participation, material-agreement and shareholder-voting developments, governance matters, capital-structure disclosure, and risk-factor updates tied to its public-company status and acquisition process.
Verve Therapeutics reported pipeline updates and financial results for the first quarter of 2024. The company dosed the first patient in the Heart-2 Phase 1b clinical trial of VERVE-102, with plans to initiate the VERVE-201 clinical trial in the second half of the year. Verve also received a milestone payment from Eli Lilly for a gene editing program targeting Lp(a). The company's cash position is strong, with $606.4 million in cash and marketable securities, providing runway into late 2026.
Verve Therapeutics announced the dosing of the first patient in the Heart-2 Phase 1b clinical trial evaluating VERVE-102, an investigational in vivo base editing medicine designed to reduce blood low-density lipoprotein cholesterol. The trial is enrolling patients with heterozygous familial hypercholesterolemia or premature coronary artery disease. VERVE-102 aims to permanently inactivate the PCSK9 gene in the liver, providing sustained reductions in LDL-C levels after a single treatment.
Verve Therapeutics granted equity awards to ten new employees under the company's 2024 Inducement Stock Incentive Plan. The employees received stock options and restricted stock units, totaling 64,200 shares and 56,100 RSUs. The options have an exercise price of $6.01 per share and will vest over four years, while the RSUs will vest annually over four years.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.